Person: GÜNDÜZ, FEYZA
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
GÜNDÜZ
First Name
FEYZA
Name
16 results
Search Results
Now showing 1 - 10 of 16
Publication Metadata only Programmed Cell Death 1 and Hepatocellular Carcinoma: An Epochal Story(SPRINGER) DEMİRTAŞ, COŞKUN ÖZER; Demirtas, Coskun Ozer; Gunduz, FeyzaIn recent years, immune-based therapies have emerged as novel pillars for hepatocellular carcinoma (HCC). The rationale of immune-checkpoint inhibitors (ICIs) trial in HCC originated from the fact that the tumor cells and the infiltrating stromal and immune cells promote an immunosuppressive tumor microenvironment, including the up-regulation of immune checkpoint molecules on their surface. Antibody-based blockage targeting inhibitory checkpoint molecules on cytotoxic T cells, including programmed cell death-1 (PD-1) or its counterpart on antigen-presenting cells has shown strong anti-tumor activity in a subset of HCC patients. Single nucleotide polymorphisms (SNP) of PD-1 gene may affect the PD-1 expression or function, which eventually can cause dysfunctionality of immune balance. Based on the inhibitory role of PD-1 in anti-tumor responses, it has been investigated in several studies as a candidate to test for genetic susceptibility of individuals to HCC. The present paper highlights the knowledge on cross-talks for liver immunology and HCC course, recent studies investigating the role of functional SNPs of PD-1 gene in Turkish HCC population, and the data on already investigated PD-1 inhibitor molecules in clinical trials.Publication Metadata only No association of PTPN22 gene polymorphism with rheumatoid arthritis in Turkey(SPRINGER HEIDELBERG, 2009) GÜNDÜZ, FEYZA; Sahin, N.; Gunduz, F.; Inanc, N.; Direskeneli, Haner; Saruhan-Direskeneli, G.Although the association of rheumatoid arthritis (RA) with HLA-DRB1 (shared epitope) is well demonstrated in many ethnic populations, the role of other RA-associated risk loci is not clarified. In this study, the functional single nucleotide polymorphism (SNP) of PTPN22 gene was investigated in Turkey. 167 patients with RA and 177 healthy controls are genotyped by polymerase chain reaction (PCR)-RFLP for the SNP (rs2476601, A/G) of PTPN22 gene. Polymorphic region was amplified by PCR and digested with Xcm I enzyme. Heterozygous genotype (AG) was present in 5.1% (9/177) of the controls and in 6.6% (11/167) of RA group (p = 0.55, OR 1.3, 95% CI 0.53-3.26). There was also no association between any clinical feature, RF positivity and presence of this SNP. In conclusion, the distribution of PTPN22 polymorphism did not reveal any association with RA in Turkey.Publication Metadata only Sertraline Hepatotoxicity: Report of a Case and Review of the Literature(SPRINGER, 2009) GÜNDÜZ, FEYZA; Tabak, Fehmi; Gunduz, Feyza; Tahan, Veysel; Tabak, Omur; Ozaras, ResatSertraline is a commonly prescribed selective serotonin reuptake inhibitor drug. Hepatotoxicity caused by sertraline is rare. Asymptomatic elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels have been rarely reported and shortly normalize after discontinuation of the agent. We present a case of severe drug-induced hepatitis in a patient receiving sertraline. To our knowledge, this is the seventh case in the medical literature as being associated with severe hepatotoxicity. Since it is extremely rare, we do not suggest a strict laboratory monitoring. However, sertraline should be discontinued in cases with symptoms implying hepatotoxicity and the patients should be informed of the potential of this side effect.Publication Metadata only Siroz hastalarında hepatosellüler karsinom taramasında altı ayda bir yapılan batın ultrasonografi ve serum alfa-feto protein ölçümüne ek olarak, yılda bir kez yapılan batın manyetik rezonans görüntülemesinin erken tanıya olan katkısı(2006-10-11) BUĞDAYCI, ONUR; GÜNDÜZ, FEYZA; ÖZDOĞAN, OSMAN CAVİT; TÜNEY, DAVUT; BUĞDAYCI O., Sever A., DİLBER F., KEDRAH A. E., TİFTİKÇİ A., AKIN H., ERZEN T. C., TÖZÜN A. N., ÖZDOĞAN O. C., TÜNEY D.Publication Metadata only The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort(2023-01-01) GÜNDÜZ, FEYZA; Yaras S., Demir M., Barutcu S., Yildirim A. E., GÜREL S., Ucbilek E., Kurtulmus I. A., Kayhan M. A., Vatansever S., ADANIR H., et al.Background and Aim: The aims of the present study were to evaluate the real-life efficacy and tolerability of glecaprevir (GLE)/pibrentasvir (PIB) in the treatment of patients with chronic hepatitis C (CHC). Materials and Methods: Between May 2019 and May 2022, 686 patients with CHC, treated with GLE/PIB combination from 21 participating centers in Turkiye, were enrolled in the study. Results: All patients were Caucasian, and their median age was 56 years. At the start of GLE/PIB treatment, the median serum Hepatitis C virus RNA and serum alanine amino transaminase (ALT) levels were 6.74 log10 IU/mL and 47 U/L, respectively. Fifty-three percent of the patients were infected with genotype 1b, followed by genotype 3 (17%). Diabetes was the more common concomitant disease. The sustained virological response (SVR12) was 91.4% with intent-to-treat analysis and 98.5% with per protocol analysis. The SVR12 rates were statistically significant differences between the patients who were i.v. drug users and non-user (88.0% vs. 98.8%, p=0.025). From the baseline to SVR12, the serum ALT levels and Model for End-Stage Liver Disease score were significantly improved (p<0.001 and p=0.014, respectively). No severe adverse effect was observed. Conclusion: GLE/PIB is an effective and tolerable treatment in patients with CHC.Publication Metadata only Letter: Is female sex an independent predictor of favourable prognosis in hepatocellular carcinoma?(WILEY, 2020) DEMİRTAŞ, COŞKUN ÖZER; Demirtas, Coskun Ozer; Gunduz, FeyzaPublication Metadata only Cleared global consortium results highlight regional variation and need for equity in inpatient outcomes in hospitalized patients with chronic liver disease(2022-07-01) GÜNDÜZ, FEYZA; Bajaj J. S., Kamath P. S., Wong F., Hayes P., İDİLMAN R., Torre A., Topazian M., George J., Reis Alvares-da-Silva M., Xie Q., et al.Publication Metadata only High treatment modification rates with lamivudine therapy in HBV-infected patients with low baseline viremia and early virological response: A multicenter study(WILEY, 2015) GÜNDÜZ, FEYZA; Gonen, Can; Gunduz, Feyza; Doganay, Levent; Enc, Feruze Y.; Yegin, Ender G.; Ahishali, Emel; Erdem, Emrullah; Sokmen, Mehmet; Tuncer, Ilyas; Ozdogan, OsmanObjectiveLow baseline viremia and an early treatment response predict the best outcomes in hepatitis B virus (HBV)-infected patients treated with nucleoside analogues with low barriers to resistance. The aim of this study was to assess the long-term results and effectiveness of lamivudine in patients with low baseline viremia and early virological treatment response. MethodsIn this multicenter, real-life setting study, 111 antiviral-naive patients with low baseline viremia (HBV DNA <10(7) copies/mL) plus an early virological response (HBV DNA <300 copies/mL at week 24) treated with lamivudine were enrolled. The primary end-point was treatment failure, defined as the re-emergence of detectable viremia or at least a 1 log increase in HBV DNA, resulting in a titer of 300 copies/mL with lamivudine treatment after week 24, which required treatment modification. ResultsAltogether 111 patients, including 78 non-cirrhotic and 33 cirrhotic patients, were included in the study. Treatment failure occurred in 30.8% of the non-cirrhotic patients over a median follow-up period of 32.5 months, and the 1-, 2-, 3-, 4- and 5-year treatment failure rates were 6.5%, 14.0%, 31.4%, 39.6% and 43.1%, respectively. Treatment failure occurred in 28.8% of the whole group. There were no differences between the cirrhotic and non-cirrhotic patients. ConclusionsLamivudine treatment had a high treatment modification rate in patients with low baseline viremia and early virological response over a long-term follow-up in a real-life setting. The pretreatment and on-treatment favorable characteristics found in the studies with telbivudine appeared to be inapplicable to lamivudine.Publication Metadata only Characteristics of Newly Diagnosed Hepatocellular Carcinoma Patients Across Turkey: Prospective Multicenter Observational 3K Registry Study(AVES, 2021) GÜNDÜZ, FEYZA; Akarca, Ulus Salih; Unsal, Belkis; Sezgin, Orhan; Yalcin, Kendal; Akdogan, Meral; Gonen, Can; Gunduz, Feyza; Ozenirler, Seren; Sonsuz, Abdullah; Dincer, Dinc; Tekin, Salim Basol; Yucel, Idris; Akbulut, Hakan; Alkim, Canan; Ozyilkan, Ozgur; Baygul, Arzu; Cevik, Zeynep Merve; Idilman, RamazanAims: To evaluate patient profile for epidemiological and clinicopathological characteristics and potential risk/prognostic factors in newly diagnosed hepatocellular carcinoma (HCC) patients across Turkey. Methods: A total of 547 patients (mean (SD) age 62.6 (10.3) years, 81.9% were males) were included in this registry study. Data on patient characteristics, etiologies of HCC, laboratory values, and tumor characteristics and stages were recorded at study enrollment. Results: HBV infection (68.2%) was the leading etiology, followed by HCV infection (17.2%), HDV infection (5.5%), alcohol (6.4%), and NAFLD (3.5%), as the major etiologies. Considering that 51.6% of the patients had >5 cm HCC, 44% were Child-Pugh B/C and 57% were BCLC B-D, it appears that a significant group of HCC patients were diagnosed at advanced stages. Of 540 patients, 271 (50.2%) were referred or applied with the diagnosis of HCC. Patients with HCC at presentation had larger tumor size (median (min-max) 6.6 (0-30) vs. 4.8 (0-90) cm, P<.001) and more advanced BCLC stage (Stage C-D in 40.8% vs. 26.4%, respectively, P=.005), compared to patients who were diagnosed during follow-up. Conclusions: Our findings revealed that HBV infection was the leading etiology and a moderate-to-advanced disease was evident in more than half of patients at the time of diagnosis. HCC patients diagnosed at follow-up had smaller tumor size and earlier BCLC stage.Publication Metadata only Eri̇şki̇nli̇kte tanı alan gli̇kojen depo ti̇p-3 olgu sunumu(2022-10-20) DİNÇER YAZAN, CEYDA; TOKAY TARHAN, SENA; GÜNDÜZ, FEYZA; YAVUZ, DİLEK; Yaşar F. Z. , Dinçer Yazan C., Tokay Tarhan S., Dilber F., Yavuz D.